Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction is a research paper published in JACC Heart Failure (2020). On theSindex it has a DataRank of 4.1. It has been cited 117 times, with 78 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.716
From this paper's citation signal
Citation Network Contribution
3.4
From 56 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 78 citers.
National Institutes of Health
Grant: R01 HL107577
National Institutes of Health
Grant: R01 HL120728
National Institutes of Health
Grant: R01 HL140731
National Institutes of Health
Grant: R01 HL149423
National Heart, Lung, and Blood Institute
Grant: T32HL094301
NCATS NIH HHS
Grant: UL1 TR002541
National Institutes of Health
Grant: 5R01HL107577-06
Determinants, Trajectories, and Consequences of Abnormal Cardiac Mechanics
National Institutes of Health
Grant: 5R01HL149423-04
Precision Medicine for Dilated Cardiomyopathy—Novel Assessment of Cardiac Mechanics via Speckle Tracking Echocardiography to Identify Early Phenotypes
National Institutes of Health
Grant: 5UL1TR002541-04
The Harvard Clinical and Translational Science Center
National Institutes of Health
Grant: 5T32HL094301-08
Noninvasive Cardiovascular Imaging Research Training Program
National Institutes of Health
Grant: 5R01HL140731-03
Machine learning for the automated identification and tracking of rare myocardial diseases
National Institutes of Health
Grant: 5R01HL120728-04
A Systems Biology Approach to Predicting Bleeding in Hemophilia
Bristol-Myers Squibb
Daiichi-Sankyo
National Medical Research Council
Novartis
Roche
AbbVie
Actavis
KU Leuven
Sanofi Pasteur
Vifor Pharma
Actelion Pharmaceuticals
AstraZeneca
Novo Nordisk
Gilead Sciences
Merck
Takeda Pharmaceuticals U.S.A.
Akebia Therapeutics
Amgen
Boehringer Ingelheim
Cytokinetics
Medtronic
Pfizer
American Heart Association
Bayer
Kidney Research UK
Baxter Healthcare Corporation
Boston Scientific Corporation
MyoKardia
Sanofi
Servier
Abbott Laboratories
Bayer Fund
GlaxoSmithKline
United Therapeutics Corporation
FWCI
11.69
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 1 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 2 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 2 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 3 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 3 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 4 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 4 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Additional file 1 of Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
Additional file 1 of Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials